(Q47567839)

4 February 2018

title

Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets (English)

1 reference

4 February 2018

1

Keith T Flaherty

1 reference

4 February 2018

publication date

3 June 2012

1 reference

4 February 2018

Clinical & Experimental Metastasis

published in

1 reference

4 February 2018

volume

29

1 reference

4 February 2018

issue

7

1 reference

4 February 2018

page(s)

841-846

1 reference

4 February 2018

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Management of cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

High frequency of BRAF mutations in nevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

A phase II trial of sorafenib in metastatic melanoma with tissue correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

21 January 2018

Melanoma and genetics

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9488-Y

NRAS mutation status is an independent prognostic factor in metastatic melanoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22661223

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22661223

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22661223

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10585-012-9488-Y

1 reference

4 February 2018

1 reference

4 February 2018